NASDAQ:AFMD Affimed - AFMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. $0.74 -0.02 (-2.63%) (As of 03/20/2023 08:20 AM ET) Add Compare Share Share Today's Range$0.74▼$0.7450-Day Range$0.76▼$1.2952-Week Range$0.74▼$5.10Volume1,088 shsAverage Volume1.27 million shsMarket Capitalization$91.33 millionP/E RatioN/ADividend YieldN/APrice Target$5.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Affimed MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside667.5% Upside$5.83 Price TargetShort InterestHealthy3.06% of Shares Sold ShortDividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment-0.02Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector296th out of 983 stocksPharmaceutical Preparations Industry128th out of 480 stocks 3.4 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.83, Affimed has a forecasted upside of 667.5% from its current price of $0.76.Amount of Analyst CoverageAffimed has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.06% of the outstanding shares of Affimed have been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Affimed has recently increased by 21.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAffimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.Environmental SustainabilityThe Environmental Impact score for Affimed is -1.95. Previous Next 2.2 News and Social Media Coverage News SentimentAffimed has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Affimed this week, compared to 2 articles on an average week.Search Interest34 people have searched for AFMD on MarketBeat in the last 30 days. This is an increase of 325% compared to the previous 30 days.MarketBeat Follows4 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by Institutions61.73% of the stock of Affimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to decrease in the coming year, from ($0.60) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Affimed is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Affimed is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAffimed has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Affimed (NASDAQ:AFMD) StockAffimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.Read More Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address AFMD Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comAffimed (NASDAQ:AFMD) Coverage Initiated at StockNews.comMarch 16, 2023 | finance.yahoo.comAffimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023March 20, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 13, 2023 | americanbankingnews.comBrokerages Set Affimed (NASDAQ:AFMD) Target Price at $5.83February 22, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Affimed (AFMD)December 28, 2022 | finance.yahoo.comInvestors in Affimed (NASDAQ:AFMD) have unfortunately lost 80% over the last yearDecember 22, 2022 | finance.yahoo.comAffimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid LeukemiaDecember 16, 2022 | finance.yahoo.comHere's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 WeeksMarch 20, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …December 12, 2022 | benzinga.comAnalyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth UpsideDecember 12, 2022 | benzinga.comCiting Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell ComboDecember 1, 2022 | finance.yahoo.comAffimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual MeetingNovember 18, 2022 | finance.yahoo.comWhy Shares of Affimed Fell ThursdayNovember 17, 2022 | finance.yahoo.comAffimed Third Quarter 2022 Earnings: Beats ExpectationsNovember 4, 2022 | finance.yahoo.comAffimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022November 2, 2022 | finance.yahoo.comAnalysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out forNovember 1, 2022 | finance.yahoo.comAffimed to Present at the 2022 Jefferies London Healthcare ConferenceOctober 21, 2022 | finance.yahoo.comWith 50% ownership, Affimed N.V. (NASDAQ:AFMD) has piqued the interest of institutional investorsOctober 10, 2022 | fool.comWhy Affimed Stock Plummeted by Over 16% Today - The Motley FoolOctober 10, 2022 | finance.yahoo.comWhy Affimed Stock Plummeted by Over 16% TodayOctober 10, 2022 | uk.investing.comDomino's Pizza To $375? Plus Stifel Cuts Price Target On This Stock By Around 78% By Benzinga - Investing.com UKOctober 10, 2022 | benzinga.comFord To Plunge 18%? Plus Mizuho Predicts $149 For PPG Industries - Affimed (NASDAQ:AFMD), Ford Motor (NYS - BenzingaOctober 10, 2022 | seekingalpha.comAffimed downgraded to hold at Stifel as pipeline lacks development clarity (NASDAQ:AFMD) - Seeking AlphaOctober 5, 2022 | streetinsider.comArtiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting - StreetInsider.comOctober 5, 2022 | finance.yahoo.comAffimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 4, 2022 | reuters.comAFMD.OQ - Affimed NV | Stock Price & Latest News | ReutersOctober 3, 2022 | reuters.comAFMD.O - Affimed NV | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address AFMD Company Calendar Last Earnings11/10/2021Today3/20/2023Next Earnings (Confirmed)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AFMD CUSIPN/A CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees197Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.83 High Stock Price Forecast$8.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+667.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,060,000.00 Net Margins-189.04% Pretax Margin-190.34% Return on Equity-48.46% Return on Assets-32.99% Debt Debt-to-Equity Ratio0.07 Current Ratio5.65 Quick Ratio5.63 Sales & Book Value Annual Sales$47.76 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book0.58Miscellaneous Outstanding Shares123,420,000Free Float118,730,000Market Cap$93.80 million OptionableOptionable Beta2.58 Key ExecutivesAdolf HoessChief Executive OfficerWolfgang FischerChief Operating OfficerAngus W. SmithChief Financial OfficerAndreas HarstrickChief Medical OfficerArndt SchotteliusChief Scientific OfficerKey CompetitorsAraviveNASDAQ:ARAVEton PharmaceuticalsNASDAQ:ETONDisc Medicine OpcoNASDAQ:IRONImmunoPrecise AntibodiesNASDAQ:IPACleneNASDAQ:CLNNView All CompetitorsInstitutional OwnershipAlliancebernstein L.P.Bought 33,600 shares on 2/16/2023Ownership: 0.134%Norges BankBought 655,600 shares on 2/15/2023Ownership: 0.531%Man Group plcBought 113,408 shares on 2/15/2023Ownership: 0.133%Alps Advisors Inc.Bought 19,452 shares on 2/15/2023Ownership: 0.080%Jane Street Group LLCSold 78,967 shares on 2/15/2023Ownership: 0.016%View All Institutional Transactions AFMD Stock - Frequently Asked Questions Should I buy or sell Affimed stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AFMD shares. View AFMD analyst ratings or view top-rated stocks. What is Affimed's stock price forecast for 2023? 6 equities research analysts have issued 12-month price objectives for Affimed's shares. Their AFMD share price forecasts range from $2.00 to $8.00. On average, they predict the company's share price to reach $5.83 in the next year. This suggests a possible upside of 667.5% from the stock's current price. View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts. How have AFMD shares performed in 2023? Affimed's stock was trading at $1.24 at the beginning of 2023. Since then, AFMD stock has decreased by 38.7% and is now trading at $0.76. View the best growth stocks for 2023 here. Are investors shorting Affimed? Affimed saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,780,000 shares, an increase of 21.5% from the February 13th total of 3,110,000 shares. Based on an average daily trading volume, of 1,700,000 shares, the days-to-cover ratio is currently 2.2 days. View Affimed's Short Interest. When is Affimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our AFMD earnings forecast. How can I listen to Affimed's earnings call? Affimed will be holding an earnings conference call on Thursday, March 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative net margin of 189.04% and a negative trailing twelve-month return on equity of 48.46%. During the same quarter in the prior year, the business posted ($0.08) EPS. What ETFs hold Affimed's stock? ETFs with the largest weight of Affimed (NASDAQ:AFMD) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN). What is Affimed's stock symbol? Affimed trades on the NASDAQ under the ticker symbol "AFMD." Who are Affimed's major shareholders? Affimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (7.29%), Point72 Asset Management L.P. (3.41%), Boone Capital Management LLC (2.33%), Morgan Stanley (1.71%), Millennium Management LLC (1.67%) and Geode Capital Management LLC (1.11%). How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Affimed's stock price today? One share of AFMD stock can currently be purchased for approximately $0.76. How much money does Affimed make? Affimed (NASDAQ:AFMD) has a market capitalization of $93.80 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. How many employees does Affimed have? The company employs 197 workers across the globe. How can I contact Affimed? Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777. This page (NASDAQ:AFMD) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.